Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer

PLoS ONE

Volumn 12, Issue 12, 2017, Pages

  Jędroszka, Dorota ^a   Orzechowska, Magdalena ^a   Hamouz, Raneem ^a   Górniak, Karolina ^a   Bednarek, Andrzej K ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ANDROPAUSE; ARTICLE; BIOLOGY; CANCER PROGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; ONCOGENE; ONCOGENE AR; ONCOGENE COL4A1; ONCOGENE CTNNB1; ONCOGENE ESR1; ONCOGENE ESR2; ONCOGENE KRT18; ONCOGENE KRT19; ONCOGENE MMP3; ONCOGENE MUC1; ONCOGENE SNAI2; ONCOGENE ZEB1; PHENOTYPE; PROSTATE CANCER; PROSTATE HYPERTROPHY; SIGNAL TRANSDUCTION; TUMOR BIOLOGY; TUMOR RECURRENCE; AGE; CANCER GRADING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PROSTATE TUMOR; VALIDATION STUDY;

AGE FACTORS; AGED; BIOMARKERS, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; PROSTATIC NEOPLASMS;

EID: 85037370794     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0188842     Document Type: Article

References (67)

1. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends - An Update. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2016 Jan; 25(1):16–27.
2. Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Prostate cancer in young men: an important clinical entity. Nat Rev Urol. 2014 Jun; 11(6):317–23. https://doi.org/10.1038/nrurol.2014.91 PMID: 24818853
3. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974 Jan; 111(1):58–64. PMID: 4813554
4. Epstein JI, Allsbrook WCJ, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005 Sep; 29(9):1228–42. PMID: 16096414
5. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016 Feb; 40(2):244–52. https://doi.org/10.1097/PAS.0000000000000530 PMID: 26492179
6. Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013 May; 111(5):753–60. https://doi.org/10.1111/j.1464-410X.2012.11611.x PMID: 23464824
7. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol Off J U S Can Acad Pathol Inc. 2004 Mar; 17(3):292–306.
8. Steinestel K, Eder S, Schrader AJ, Steinestel J. Clinical significance of epithelial-mesenchymal transition. Clin Transl Med. 2014; 3:17. https://doi.org/10.1186/2001-1326-3-17 PMID: 25050175
9. Nauseef JT, Henry MD. Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol. 2011 Jun 21; 8(8):428–39. https://doi.org/10.1038/nrurol.2011.85 PMID: 21691304
10. Bastid J. EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations. Cancer Metastasis Rev. 2012 Jun; 31(1–2):277–83. https://doi.org/10.1007/s10555-011-9344-6 PMID: 22215472
11. Hussein S, Satturwar S, Van der Kwast T. Young-age prostate cancer. J Clin Pathol. 2015 Jul; 68 (7):511–5. https://doi.org/10.1136/jclinpath-2015-202993 PMID: 25837493
12. Yadav N, Heemers HV. Androgen action in the prostate gland. Minerva Urol E Nefrol Ital J Urol Nephrol. 2012 Mar; 64(1):35–49.
13. Lau K-M, To K-F. Importance of Estrogenic Signaling and Its Mediated Receptors in Prostate Cancer. Int J Mol Sci. 2016 Aug 31; 17(9).
14. Orwoll E, Lambert LC, Marshall LM, Phipps K, Blank J, Barrett-Connor E, et al. Testosterone and estradiol among older men. J Clin Endocrinol Metab. 2006 Apr; 91(4):1336–44. https://doi.org/10.1210/jc.2005-1830 PMID: 16368750
15. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009 Jun; 119(6):1420–8. https://doi.org/10.1172/JCI39104 PMID: 19487818
16. Ye X, Weinberg RA. Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. Trends Cell Biol. 2015 Nov; 25(11):675–86. https://doi.org/10.1016/j.tcb.2015.07.012 PMID: 26437589
17. Lee K, Nelson CM. New insights into the regulation of epithelial-mesenchymal transition and tissue fibrosis. Int Rev Cell Mol Biol. 2012; 294:171–221. https://doi.org/10.1016/B978-0-12-394305-7.00004-5 PMID: 22364874
18. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 2002 Feb 15; 62(4):1008–13. PMID: 11861374
19. Lee D. High androgen receptor levels are predictive of decreased survival in prostate cancer. Clin Prostate Cancer. 2003 Jun; 2(1):13–4. PMID: 15046676
20. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997 Jan 15; 57(2):314–9. PMID: 9000575
21. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995 Apr; 9 (4):401–6. https://doi.org/10.1038/ng0495-401 PMID: 7795646
22. Ricciardelli C, Choong CS, Buchanan G, Vivekanandan S, Neufing P, Stahl J, et al. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. The Prostate. 2005 Apr 1; 63(1):19–28. https://doi.org/10.1002/pros.20154 PMID: 15378523
23. Dong P, Jiang L, Liu J, Wu Z, Guo S, Zhang Z, et al. Induction of paclitaxel resistance by ERalpha mediated prohibitin mitochondrial-nuclear shuttling. PloS One. 2013; 8(12):e83519. https://doi.org/10.1371/journal.pone.0083519 PMID: 24376711
24. Corey E, Quinn JE, Emond MJ, Buhler KR, Brown LG, Vessella RL. Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol. Clin Cancer Res Off J Am Assoc Cancer Res. 2002 Apr; 8(4):1003–7.
25. Atala A. Re: Estrogen receptor beta upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer. J Urol. 2015 May; 193(5):1725.
26. Dey P, Jonsson P, Hartman J, Williams C, Strom A, Gustafsson J-A. Estrogen receptors beta1 and beta2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3. Mol Endocrinol Baltim Md. 2012 Dec; 26(12):1991–2003.
27. Powell E, Shanle E, Brinkman A, Li J, Keles S, Wisinski KB, et al. Identification of estrogen receptor dimer selective ligands reveals growth-inhibitory effects on cells that co-express ERalpha and ERbeta. PloS One. 2012; 7(2):e30993. https://doi.org/10.1371/journal.pone.0030993 PMID: 22347418
28. Christoforou P, Christopoulos PF, Koutsilieris M. The role of estrogen receptor beta in prostate cancer. Mol Med Camb Mass. 2014 Oct 2; 20:427–34. https://doi.org/10.2119/molmed.2014.00105 PMID: 25032955
29. Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Estrogen receptors alpha (rs2234693 and rs9340799), and beta (rs4986938 and rs1256049) genes polymorphism in prostate cancer: evidence for association with risk and histopathological tumor characteristics in Iranian men. Mol Carcinog. 2012 Oct; 51 Suppl 1:E104–117.
30. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J Off Publ Fed Am Soc Exp Biol. 2008 May; 22(5):1512–20.
31. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol. 2001 Jul; 159(1):79–92. PMID: 11438457
32. Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from development. Dev Camb Engl. 2012 Oct; 139(19):3471–86.
33. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009 Nov 25; 139(5):871–90. https://doi.org/10.1016/j.cell.2009.11.007 PMID: 19945376
34. Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol. 2004; 48(5–6):365–75. https://doi.org/10.1387/ijdb.041794hp PMID: 15349812
35. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000 Feb; 2(2):84–9. https://doi.org/10.1038/35000034 PMID: 10655587
36. Thiery JP. The saga of adhesion molecules. J Cell Biochem. 1996 Jun 15; 61(4):489–92. https://doi.org/10.1002/(SICI)1097-4644(19960616)61:4<489::AID-JCB1>3.0.CO;2-K PMID: 8806071
37. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 1992 Sep 15; 52(18):5104–9. PMID: 1516067
38. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994 Jul 15; 54(14):3929–33. PMID: 7518346
39. Mooney SM, Jolly MK, Levine H, Kulkarni P. Phenotypic plasticity in prostate cancer: role of intrinsically disordered proteins. Asian J Androl. 2016 Oct; 18(5):704–10. https://doi.org/10.4103/1008-682X.183570 PMID: 27427552
40. Jiang Y-G, Luo Y, He D, Li X, Zhang L, Peng T, et al. Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha. Int J Urol Off J Jpn Urol Assoc. 2007 Nov; 14(11):1034–9.
41. Kypta RM, Waxman J. Wnt/beta-catenin signalling in prostate cancer. Nat Rev Urol. 2012 Aug; 9 (8):418–28. https://doi.org/10.1038/nrurol.2012.116 PMID: 22710668
42. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004 Mar 5; 303(5663):1483–7. https://doi.org/10.1126/science.1094291 PMID: 15001769
43. Labbe E, Letamendia A, Attisano L. Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-beta and wnt pathways. Proc Natl Acad Sci U S A. 2000 Jul 18; 97(15):8358–63. https://doi.org/10.1073/pnas.150152697 PMID: 10890911
44. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology (Phila). 2007 Jun; 39(3):305–18.
45. Saha B, Arase A, Imam SS, Tsao-Wei D, Naritoku WY, Groshen S, et al. Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone. The Prostate. 2008 Jan 1; 68 (1):78–84. https://doi.org/10.1002/pros.20670 PMID: 18008331
46. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ, et al. Cadherin switching in human prostate cancer progression. Cancer Res. 2000 Jul 1; 60(13):3650–4. PMID: 10910081
47. Tran NL, Nagle RB, Cress AE, Heimark RL. N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion withStromal cells. Am J Pathol. 1999 Sep; 155(3):787–98. https://doi.org/10.1016/S0002-9440(10)65177-2 PMID: 10487836
48. Bussemakers MJ, Van Bokhoven A, Tomita K, Jansen CF, Schalken JA. Complex cadherin expression in human prostate cancer cells. Int J Cancer. 2000 Feb 1; 85(3):446–50. PMID: 10652439
49. Halbleib JM, Nelson WJ. Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev. 2006 Dec 1; 20(23):3199–214. https://doi.org/10.1101/gad.1486806 PMID: 17158740
50. Jaggi M, Johansson SL, Baker JJ, Smith LM, Galich A, Balaji KC. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol Oncol. 2005 Dec; 23(6):402–6. https://doi.org/10.1016/j.urolonc.2005.03.024 PMID: 16301117
51. Drake JM, Strohbehn G, Bair TB, Moreland JG, Henry MD. ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells. Mol Biol Cell. 2009 Apr; 20(8):2207–17. https://doi.org/10.1091/mbc.E08-10-1076 PMID: 19225155
52. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, et al. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2008 Apr 1; 68(7):2479–88. https://doi.org/10.1158/0008-5472.CAN-07-2559 PMID: 18381457
53. Anose BM, LaGoo L, Schwendinger J. Characterization of androgen regulation of ZEB-1 and PSA in 22RV1 prostate cancer cells. Adv Exp Med Biol. 2008; 617:541–6. https://doi.org/10.1007/978-0-387-69080-3_55 PMID: 18497080
54. Moody SE, Perez D, Pan T, Sarkisian CJ, Portocarrero CP, Sterner CJ, et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell. 2005 Sep; 8(3):197–209. https://doi.org/10.1016/j.ccr.2005.07.009 PMID: 16169465
55. Deep G, Jain AK, Ramteke A, Ting H, Vijendra KC, Gangar SC, et al. SNAI1 is critical for the aggressiveness of prostate cancer cells with low. Mol Cancer. 2014 Feb 24; 13:37. https://doi.org/10.1186/1476-4598-13-37 PMID: 24565133
56. Guaita S, Puig I, Franci C, Garrido M, Dominguez D, Batlle E, et al. Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J Biol Chem. 2002 Oct 18; 277(42):39209–16. https://doi.org/10.1074/jbc.M206400200 PMID: 12161443
57. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene. 2009 Oct 8; 28(40):3573–85. https://doi.org/10.1038/onc.2009.214 PMID: 19633685
58. Deryugina EI, Quigley JP. Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol J Int Soc Matrix Biol. 2015 Jul; 44–46:94–112.
59. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005 May 25; 1755(1):37–69. https://doi.org/10.1016/j.bbcan.2005.03.001 PMID: 15907591
60. Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer. 2009 Jul 1; 115(13):2863–71. https://doi.org/10.1002/cncr.24324 PMID: 19466697
61. Merrill RM, Bird JS. Effect of young age on prostate cancer survival: a population-based assessment (United States). Cancer Causes Control CCC. 2002 Jun; 13(5):435–43. PMID: 12146848
62. Huang T-H, Kuo J-Y, Huang Y-H, Chung H-J, Huang WJS, Wu HHH, et al. Prostate cancer in young adults-Seventeen-year clinical experience of a single center. J Chin Med Assoc JCMA. 2017 Jan; 80(1):39–43. https://doi.org/10.1016/j.jcma.2016.10.004 PMID: 27914715
63. Milonas D, Venclovas Z, Gudinaviciene I, Zviniene K, Matjosaitis AJ. Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer. BioMed Res Int. 2017; 2017:9858923. https://doi.org/10.1155/2017/9858923 PMID: 28299340
64. Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015 Nov 5; 163(4):1011–25. https://doi.org/10.1016/j.cell.2015.10.025 PMID: 26544944
65. Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PloS One. 2012; 7(12):e51862. https://doi.org/10.1371/journal.pone.0051862 PMID: 23251644
66. Lê S, Josse J, Husson F. FactoMineR: An R package for multivariate analysis. J Stat Softw. 2008; 25(1):1–18.
67. Team RC. R: A language and environment for statistical computing. R Found Stat Comput Vienna Austria. 2017;